ArticleInternational urology and nephrology2026
High-density lectin microarray uncovers stage-specific plasma glycoprofiling signatures for non-muscle-invasive and muscle-invasive bladder cancer.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesThe critical need for minimally invasive biomarkers to stratify non-muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC) prompted our investigation into tumor-specific glycan signatures. We hypothesized that lectin-based glycoprofiling could stratify MIBC and NMIBC via stage-specific glycan remodeling. Leveraging the emerging role of lectin microarrays in glycoprofiling, the first comprehensive plasma-based analysis comparing NMIBC and MIBC glycosylation patterns using a high-density 95-lectin platform was conducted.
methodsA pilot cohort of 48 plasma samples (22 NMIBC, 10 MIBC, 16 NL) was analyzed using RayBiotech's high-density 95-lectin microarray platform (GA-Lectin-95). Advanced bioinformatics pipelines (Limma package, R/Bioconductor) identified differentially expressed lectins (LogFC > 1.2, adj.p < 0.05) with stringent validation, including ROC analysis (Receiver Operating Characteristic, pROC package) and cross-validated AUC (Area Under the Curve) calculations.
resultsStage-specific glycoarchitectural remodeling revealed profound pathophysiological divergence: NMIBC plasma exhibited global glycan depletion marked by SSA/ASA/SHA downregulation (diagnostic AUC 0.79-1.00), whereas MIBC demonstrated aggressive sialylation/fucosylation signatures dominated by VVA/WFA overexpression (AUC 0.91-0.95). A decalectin panel in DSA/ASA/STL/ABL/MNM-M/PWA/PTL-1/SSA/CAA/GAL3C-S achieved perfect stratification of NMIBC from controls (AUC = 1.00), while four invasion-associated lectin complexes GAL1-S/RCA60/MPL/LSL-N showed MIBC-specific amplification (AUC > 0.80). Notably, CAA/DSA/SSA precisely discriminated MIBC from NMIBC (AUC = 1.00). GAL2 emerged as a novel metastasis checkpoint through its dramatic suppression in invasive tumors, suggesting its role as a glycosylation gatekeeper restraining muscle invasion.
conclusionsThese findings support plasma glycoprofiling as a paradigm-shifting tool for bladder cancer subtyping. The results of this study provide actionable biomarkers for clinical stratification and diagnostics applications in bladder cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.